ArticleDiscover oncology2026

DLX2 marks an immunosuppressive dendritic-cell program that reshapes cytotoxic immunity and marks a tolerogenic microenvironment in lung adenocarcinoma.

Heng Tian et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.